Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03963414 · ClinicalTrials.gov registry record · Phase 1
A Study of Durvalumab Plus Tremelimumab With Chemotherapy in Untreated ES-SCLC
A Phase 1 study, sponsored by University of Nebraska.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT03963414 is a Phase 1 study that was terminated before completion, run by University of Nebraska. The registered enrollment target is 1 participants.
The verdict
NCT03963414, a Phase 1 study, was terminated before completion, sponsored by University of Nebraska.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
This study is designed to evaluate the safety and tolerability of durvalumab and tremelimumab in combination with intravenous (IV) carboplatin plus (+) etoposide in new patients with extensive-stage small cell lung cancer (ES-SCLC).
Interventions
- COMBINATION_PRODUCT Durvalumab + Tremelimumab in combination with carboplatin and etoposide
- COMBINATION_PRODUCT Durvalumab in combination with carboplatin and etoposide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2020-09-25 |
| Est. Completion | 2021-12-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03963414
The ClinicalTrials.gov registry entry for NCT03963414 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Nebraska, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Durvalumab + Tremelimumab in combination with carboplatin and etoposide is the first listed.
NCT03963414 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03963414 about?
NCT03963414 is a clinical study titled "A Study of Durvalumab Plus Tremelimumab With Chemotherapy in Untreated ES-SCLC". This study is designed to evaluate the safety and tolerability of durvalumab and tremelimumab in combination with intravenous (IV) carboplatin plus (+) etoposide in new patients with extensive-stage small cell lung cancer (ES-SCLC).
What is the current status of trial NCT03963414?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2020-09-25. Estimated completion is 2021-12-15.
What interventions are being tested in trial NCT03963414?
The interventions under investigation include: Durvalumab + Tremelimumab in combination with carboplatin and etoposide (COMBINATION_PRODUCT), Durvalumab in combination with carboplatin and etoposide (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT03963414?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.